What it is
Cagrilintide is a long-acting amylin analog designed to support sustainable weight management. It enhances satiety, reduces appetite, and helps regulate food intake, making a calorie deficit easier to maintain. It also helps stabilise blood sugar and improve insulin sensitivity.
Mechanism of action
Activates calcitonin and amylin receptors in the hindbrain, particularly in the area postrema and nucleus tractus solitarius, slowing gastric emptying and amplifying meal-related satiety signals. Acts on amylin receptors 1 and 3.
Half-life: ~6 days — supports once-weekly dosing.
Evidence summary
Phase 1/2 monotherapy trials show ~10% weight loss at high dose. 2025 review work outlines its place in the next-generation incretin landscape.
Pantheon dosing guide
- Application
- Subcutaneous injection.
- BAC Water
- 5 mg: 2 ml 10 mg: 2 ml
- Dose
- 5 mg: 10 units (250 mcg) to 20 units (500 mcg). 10 mg: 5 units (250 mcg) to 10 units (500 mcg).
- Frequency & Cycle Length
- Once a week. Start with 250 to 500 mcg/week for 4 weeks. After 4 weeks, increase by 0.5 to 1 mg weekly if needed. Do not exceed 4.5 mg per week.
- Timing
- Take in the morning. Take same day each week to maintain stable blood levels.
- Key Benefits
- Supports weight loss. Suppresses appetite. Improves metabolic health. Enhances insulin sensitivity.
Additional research protocol context
The printed guide above is Pantheon's dosing reference. These broader research examples are provided as context and may use different schedules.
- Start 0.3 mg subcutaneous weekly; titrate every 4 weeks
- Maintenance: 1.2–2.4 mg weekly
- Often studied for appetite-control and metabolic-support protocols
Side effects & safety
- GI: nausea, vomiting, diarrhea (peaks during titration)
- Hypoglycemia risk modest unless combined with insulin/sulfonylurea
- Injection-site irritation possible
Cited studies
- (2025). Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. Nature Communications (NLM).Read source ↗
- (2025). What clinical trials have been conducted for Cagrilintide?. Synapse / Patsnap.Read source ↗
- (2025). The next frontier in metabolic health: Cagrilintide and the evolving landscape of therapies. The Innovation Medicine.Read source ↗
All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.